Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Apply
Tolvaptan
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step